Abstract
Schizophrenia affects approximately 1% of the world population, and the majority of pharmacologically based treatments for this disorder are ligands that interact with monoaminergic transmission. However, there is a wealth of evidence that various neuropeptides are often co-released with monoamine neurotransmitters, and that ligands acting at neuropeptide receptors modulate monoaminergic transmission as well as schizophrenia-related behaviors in preclinical animal models. Such neuropeptide systems include neurotensin, cholecystokinin, corticotropin releasing factor, neuropeptide Y, oxytocin, opioid peptides, tachykinins, thyrotropin-releasing hormone, and orexins. The purpose of this review will be to summarize the existing preclinical and clinical literature on the role of various neuropeptide systems as modulators of schizophrenia-related behaviors, and the potential of targeting these systems for the development of novel antipsychotic medications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 619-632 |
| Number of pages | 14 |
| Journal | CNS and Neurological Disorders - Drug Targets |
| Volume | 12 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2013 |
Keywords
- Antipsychotic
- Cognitive deficits
- Dopamine
- Negative symptoms
- Neuropeptide
- Positive symptoms
- Schizophrenia
ASJC Scopus subject areas
- Neuroscience(all)
- Pharmacology